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Erratum
In the article by Wang et al. [1] published in the April 2013 issue of Translational Oncology, the Figure 2B used was incorrect. For the Western
blotting of PLC-beta 3, an incorrect image was used for L3.6pl cell line (the middle panel). The blot images for Colo357 and HPAC cell lines
are correct. Note that this error does not affect the interpretation of the results or the conclusions of this paper. Shown below is the correct figure.
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Figure 2. CXCR2 and PLC-β3 in PDAC cells preferentially interact with NHERF1. (A) Endogenous CXCR2 (from indicated PDAC cells) was
pulled down by PDZ scaffold protein (NHERF1, NHERF2, or PDZK1). The membrane was blotted with anti-CXCR2 antibody. (B) Endog-
enous PLC-β3 (from indicated PDAC cells) was pulled down by PDZ scaffold protein (NHERF1, NHERF2, or PDZK1). Themembrane was
blotted with anti–PLC-β3 antibody. (C) Endogenous PLC-β3 was pulled down by NHERF1 in a dose-dependent manner. (D) Pairwise
binding between GST-NHERF1 and His-S–tagged PLC-β3 C-tails (containing the last 100 amino acids) WT, PDZ motif deletion (ΔTQL),
or PDZ motif mutant (AAA). The complex was pulled down by S-protein agarose and immunoblotted with anti-NHERF1 antibody.
